Suzuki Etsu, Fujita Daishi, Takahashi Masao, Oba Shigeyoshi, Nishimatsu Hiroaki
Etsu Suzuki, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki 216-8512, Japan.
World J Nephrol. 2016 Jan 6;5(1):43-52. doi: 10.5527/wjn.v5.i1.43.
Kidney regeneration is a challenging but promising strategy aimed at reducing the progression to end-stage renal disease (ESRD) and improving the quality of life of patients with ESRD. Adult stem cells are multipotent stem cells that reside in various tissues, such as bone marrow and adipose tissue. Although intensive studies to isolate kidney stem/progenitor cells from the adult kidney have been performed, it remains controversial whether stem/progenitor cells actually exist in the mammalian adult kidney. The efficacy of mesenchymal stem cells (MSCs) in the recovery of kidney function has been demonstrated in animal nephropathy models, such as acute tubular injury, glomerulonephritis, renal artery stenosis, and remnant kidney. However, their beneficial effects seem to be mediated largely via their paracrine effects rather than their direct differentiation into renal parenchymal cells. MSCs not only secrete bioactive molecules directly into the circulation, but they also release various molecules, such as proteins, mRNA, and microRNA, in membrane-covered vesicles. A detailed analysis of these molecules and an exploration of the optimal combination of these molecules will enable the treatment of patients with kidney disease without using stem cells. Another option for the treatment of patients with kidney disease using adult somatic cells is a direct/indirect reprogramming of adult somatic cells into kidney stem/progenitor cells. Although many hurdles still need to be overcome, this strategy will enable bona fide kidney regeneration rather than kidney repair using remnant renal parenchymal cells.
肾脏再生是一项具有挑战性但前景广阔的策略,旨在减缓终末期肾病(ESRD)的进展,并提高ESRD患者的生活质量。成体干细胞是存在于各种组织(如骨髓和脂肪组织)中的多能干细胞。尽管已经开展了大量从成年肾脏中分离肾脏干/祖细胞的研究,但哺乳动物成年肾脏中是否实际存在干/祖细胞仍存在争议。间充质干细胞(MSCs)在动物肾病模型(如急性肾小管损伤、肾小球肾炎、肾动脉狭窄和残余肾)中对肾功能恢复的功效已得到证实。然而,它们的有益作用似乎主要是通过旁分泌效应介导的,而不是直接分化为肾实质细胞。MSCs不仅直接向循环系统分泌生物活性分子,还通过膜包被囊泡释放各种分子,如蛋白质、mRNA和微小RNA。对这些分子进行详细分析并探索这些分子的最佳组合,将能够在不使用干细胞的情况下治疗肾病患者。使用成体体细胞治疗肾病患者的另一种选择是将成体体细胞直接/间接重编程为肾脏干/祖细胞。尽管仍有许多障碍需要克服,但这种策略将实现真正的肾脏再生,而不是利用残余肾实质细胞进行肾脏修复。